Company news
Korro Bio, Inc. news in 2020
Korro Bio, Inc.'s news releases, calls and decks from 2020, newest first.
Frequency Therapeutics to Host Investor Event on the Potential for Restorative Treatments for Acquired Sensorineural Hearing Loss
December 17, 2020
Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer
November 30, 2020
Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2020 Financial Results
November 15, 2020
Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis
October 28, 2020
Frequency Therapeutics Appoints Cynthia Feldmann to its Board of Directors
September 24, 2020
Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss
September 21, 2020
Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322
September 12, 2020
Frequency Therapeutics to Present at Upcoming Investor Conferences and Medical Meetings
September 7, 2020
Frequency Therapeutics Provides Business Updates and Reports Second Quarter 2020 Financial Results
August 11, 2020
Frequency Therapeutics Announces $42 Million Private Placement
July 16, 2020
Frequency Therapeutics Shares Clinical Data From Exploratory Study Confirming Delivery of FX-322 to the Cochlea
May 13, 2020
Frequency Therapeutics Provides Business Updates and Reports First Quarter 2020 Financial Results
May 13, 2020
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2019 Financial Results
March 25, 2020
Frequency Therapeutics to Present at the 40th Annual Cowen Healthcare Conference
February 20, 2020
Frequency Therapeutics Expands Leadership Team with Newly Appointed Chief People Officer and Head of Intellectual Property
February 6, 2020
Frequency Therapeutics to Present Business and Pipeline Overview at the 38th Annual J.P. Morgan Healthcare Conference
January 6, 2020